OTCMKTS:MEOBFMesoblast Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mesoblast limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.70 0.00 (0.00 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$2.70Now: $2.70▼$2.7050-Day Range$2.05MA: $2.26▼$2.7052-Week Range$0.90Now: $2.70▼$3.90VolumeN/AAverage Volume34,217 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsHeadlinesSocial Media Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Mesoblast. Previous Next 2.7 Community Rank Outperform VotesMesoblast has received 57 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMesoblast has received 48 “underperform” votes. (Add your “underperform” vote.)Community SentimentMesoblast has received 54.29% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote “Outperform” if you believe MEOBF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MEOBF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMesoblast does not currently pay a dividend.Dividend GrowthMesoblast does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mesoblast insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.54 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:MEOBF Previous Symbol CUSIPN/A CIKN/A Webwww.mesoblast.com Phone61 3 9639 6036Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees81 Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable $2.70 0.00 (0.00 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MEOBF News and Ratings via Email Sign-up to receive the latest news and ratings for MEOBF and its competitors with MarketBeat's FREE daily newsletter. Mesoblast (OTCMKTS:MEOBF) Frequently Asked Questions How has Mesoblast's stock been impacted by COVID-19 (Coronavirus)? Mesoblast's stock was trading at $1.45 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MEOBF stock has increased by 86.2% and is now trading at $2.70. View which stocks have been most impacted by Coronavirus. Has Mesoblast been receiving favorable news coverage? News stories about MEOBF stock have been trending somewhat positive recently, according to InfoTrie. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mesoblast earned a daily sentiment score of 1.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Mesoblast. Who are some of Mesoblast's key competitors? Some companies that are related to Mesoblast include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Admedus (AHZ), Almirall (LBTSF), Amarantus Bioscience (AMBS), Antibe Therapeutics (VBIZF), Aortech International (RUA), Apotheca Biosciences (CBDC), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Baudax Bio (BXRXV), BerGenBio ASA (BRRGF), Biocure Technology (CURE) and Canada House Wellness Group (CHV). View all competitors. Who are Mesoblast's key executives? Mesoblast's management team includes the following people: Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 62)Dr. Donna L. Skerrett, Chief Medical Officer (Age 62)Mr. Roger D. Brown BA, Head of Spinal Orthopedic DisordersMr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 42)Dr. Kenneth M. Borow M.D., Exec. (Age 71) What is Mesoblast's stock symbol? Mesoblast trades on the OTCMKTS under the ticker symbol "MEOBF." How do I buy shares of Mesoblast? Shares of MEOBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Mesoblast's stock price today? One share of MEOBF stock can currently be purchased for approximately $2.70. What is Mesoblast's official website? The official website for Mesoblast is www.mesoblast.com. How can I contact Mesoblast? The company can be reached via phone at 61 3 9639 6036. This page was last updated on 8/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
